Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial source : Www.aquestive.com save search
Aquestive Therapeutics Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen®
Published: 2022-09-27 (Crawled : 12:00) - aquestive.com
AQST | $3.905 -8.76% -9.6% 2.1M
|
Health Technology
|
| O: 12.05%
H: 1.2%
C: -9.16%
aqst-109 epipen trial therapeutics positive
Aquestive Therapeutics Reports Positive Initial Topline Data from Part 3 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film
Published: 2022-06-15 (Crawled : 21:00) - aquestive.com
AQST | $3.905 -8.76% -9.6% 2.1M
|
Health Technology
|
| O: -2.74%
H: 4.65%
C: -15.49%
aqst-109 topline trial therapeutics epinephrine positive
Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergi
Published: 2021-10-25 (Crawled : 13:00) - aquestive.com
AQST | $3.905 -8.76% -9.6% 2.1M
|
Health Technology
|
| O: 1.64%
H: 9.45%
C: 7.6%
treatment epinephrine phase 1 positive topline drug trial merge
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.